Gary S. Titus,
Mr. Titus was appointed as a director in December 2012 and as Chairman in September 2015. He has more than 20 years of business experience in the healthcare and biopharmaceutical industries, primarily in senior management roles. He is currently serving as Chief Financial Officer of UroGen Pharma, LTD. Prior to UroGen Pharma, Mr. Titus served as Chief Financial Officer of BioCardia Inc., a development stage cardiovascular company. Previously, Mr. Titus served as Senior Vice President and Chief Financial Officer at SciClone Pharmaceuticals, Inc., Senior Vice President of Finance and Chief Financial Officer at Kosan Biosciences (acquired by Bristol-Myers Squibb), and Chief Financial Officer and Vice President at Nuvelo, Inc. Earlier in his career, Mr. Titus held a variety of positions with increasing management responsibilities at Metabolex, Inc., Intrabiotics Pharmaceuticals, Inc., and Johnson & Johnson’s healthcare division LifeScan, Inc.
Mr. Titus earned a Bachelor of Science degree in Accounting from University of South Florida and a Bachelor of Science degree in Finance from University of Florida and is a Certified Public Accountant (inactive). He also completed the Global BioExecutive Program at UC Berkeley’s Haas School of Business and is a member of several professional organizations.
Anthony Gringeri, PhD,
President and CEO
Dr. Gringeri was appointed Chief Executive Officer in December 2016. He joined ImmunoCellular Therapeutics in August 2013 as Senior Vice President, Strategic Resources. Dr. Gringeri has more than 25 years of executive experience in the pharmaceutical and biotechnology industry, having successfully led multiple functions and cross-functional teams throughout his career, including in the areas of clinical, regulatory and commercial planning and operations, finance, licensing and alliance management. He joined ImmunoCellular from ViaCyte, where he was Vice President and Chief Development Officer, responsible for all preclinical, clinical and regulatory activities. Previously, Dr. Gringeri served as Chief Operating Officer for Amsterdam Molecular Therapeutics, where he was responsible for corporate strategy and operations, business development, building the company’s commercial capability, and played a key role in its initial public offering. Dr. Gringeri worked with Amgen for 15 years in a series of executive leadership roles. Dr. Gringeri was the Vice President, Product Development, responsible for the successful development and commercialization of ARANESP® (darbepoetin alfa). Dr. Gringeri holds a PhD in pharmacology from the University of Rochester and has authored multiple scientific publications.
Rahul Singhvi, Sc.D., MBA
Dr. Singhvi was appointed a director in 2010. He is the Chief Operating Officer of Takeda Vaccines, Inc. and is responsible for Takeda’s global vaccine operations. He has deep experience in both vaccine development and manufacturing. Before joining Takeda, Dr. Singhvi was President and CEO of Novavax, a biopharmaceutical company focused on developing novel, highly potent recombinant vaccines. Prior to joining Novovac, Dr. Singhvi served in various positions with Merck & Co., Inc., culminating as Director of the Merck Manufacturing Division, where he helped develop several vaccines, including Zostavax® the only vaccine on the market to prevent shingles.
Dr. Singhvi received his MS and ScD degrees in chemical engineering from the Massachusetts Institute of Technology, and holds a MBA degree from the Wharton School.
John S. Yu, M.D.,
Dr. Yu is ImmunoCellular Therapeutics’ Founder and is a member of the full-time faculty in the Department of Neurosurgery at Cedars-Sinai Medical Center. An internationally renowned neurosurgeon, Dr. Yu's clinical focus is on the treatment of malignant and benign brain and spinal tumors. In addition, he is conducting in-depth research in immune and gene therapy for brain tumors. He has also extensively studied the use of neural stem cells as delivery vehicles for brain cancers and neurodegenerative diseases.
Dr. Yu was inducted into Castle and Connelly's America's Top Doctors in 2005 and has published articles in a number of prestigious journals, including The Lancet, Cancer Research, Cancer Gene Therapy, Human Gene Therapy, Journal of Neuroimmunology, Journal of Neurological Science and Journal of Neurosurgery.
Dr. Yu earned his bachelor's degree in French literature and biological sciences from Stanford University and spent a year at the Sorbonne in Paris studying French literature while pursuing a fellowship in immunology at the Institut Pasteur in Paris. He earned his medical degree from Harvard Medical School and master's degree from the Harvard University's Department of Genetics. He completed his neurosurgical residency at Massachusetts General Hospital (MGH) in Boston. In addition, he was a Neuroscience Fellow at the National Institutes of Mental Health in the Neuroimmunology Unit at MGH from 1988 to 1989 and was a Culpepper Scholar in the hospital’s Molecular Neurogenetics Unit from 1993 to 1995.
Dr. Yu's other honors include the Preuss Award, Joint Section on Tumors, American Association of Neurological Surgeons and Congress of Neurologic Surgeons in 1995. He received the Academy Award from the American Academy of Neurological Surgery at its 1996 annual meeting. Other honors include the Young Investigator Award from the Congress of Neurological Surgeons in 2000, the National Brain Tumor Foundation Grant in 2001, and the Mahaley Clinical Research award from the American Association of Neurological Surgeons in 2005.
Gregg A. Lapointe
Mr. Lapointe is currently the Chief Executive Officer of Cerium Pharmaceuticals, Inc., a specialty pharmaceutical company. He previously served as Chief Operating Officer and then as Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc., a pharmaceutical company focused on rare disorders and the U.S. wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A.
Lapointe is a Certified Public Accountant (Illinois). He holds a Bachelor of Commerce degree from Concordia University of Montreal, a Graduate Diploma in Public Accountancy from McGill University of Montreal and a Master of Business Administration degree from Duke University. Mr. Lapointe also serves on the Boards of Directors of SciClone Pharmaceuticals, Inc., Soligenix, Inc., and Raptor Pharmaceuticals Corp.
Mark A. Schlossberg
Mr. Schlossberg currently serves as Senior Vice President, General Counsel and Corporate Secretary of Impax Laboratories, Inc., where he is part of the senior management team responsible for the strategic direction and financial condition of the company. He leads the legal team and previously had responsibility for the healthcare compliance team. Prior to Impax, he served as Vice President, Associate General Counsel of Amgen Inc., where he led the legal department, and was responsible for corporate governance, securities law, licensing, mergers and acquisitions, global operations, and sales and marketing compliance.
Prior to joining Amgen, he held legal and business positions at Medtronic, Inc., and legal positions at Diageo plc, RJR Nabisco, Inc. and Mudge Rose Guthrie Alexander & Ferdon. Mr. Schlossberg holds a Bachelor of Sciences in business administration, finance from the University of Southern California and a Juris Doctor degree from Emory University.